nach oben

Erschienen in:

13.11.2017 | Original Article

DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer

verfasst von: Noor Ahmed Nahid, Mohd Nazmul Hasan Apu, Md. Reazul Islam, Samia Shabnaz, Surid Mohammad Chowdhury, Maizbha Uddin Ahmed, Zabun Nahar, Md. Siddiqul Islam, Mohammad Safiqul Islam, Abul Hasnat

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Significant inter-individual variation in the sensitivity to 5-fluorouracil (5-FU) represents a major therapeutic hindrance either by impairing drug response or inducing adverse drug reactions (ADRs). This study aimed at exploring the cause behind this inter-individual alterations in consequences of 5-fluorouracil-based chemotherapy by investigating the effects of DPYD*2A and MTHFR C677T polymorphisms on toxicity and response of 5-FU in Bangladeshi colorectal cancer patients.

Methods

Colorectal cancer patients (n = 161) receiving 5-FU-based chemotherapy were prospectively enrolled. DPYD and MTHFR polymorphisms were assessed in peripheral leukocytes. Multivariate analyses were applied to evaluate which variables could predict chemotherapy-induced toxicity and efficacy.

Results

Multivariate analyses showed that DPYD*2A polymorphism was a predictive factor (P = 0.023) for grade 3 and grade 4 5-fluorouracil-related toxicities. Although MTHFR C677T polymorphism might act as forecasters for grade 3 or grade 4 neutropenia, diarrhea, and mucositis, this polymorphism was found to increase significantly (P = 0.006) the response of 5-FU.

Conclusion

DPYD*2A and MTHFR C677T polymorphisms could explain 5-FU toxicity or clinical outcome in Bangladeshi colorectal patients.

Ferlay J, Ferlay J, Soerjomataram I et al. (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. http://globocan.iarc.fr. Accessed on 10 Apr 2015

Heidelberger C, Chaudhuri NK, Danneberg P et al (1957) Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179(4561):663–666PubMedCrossRef

Giacchetti S, Perpoint B, Zidani R et al (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil–leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18(1):136–147PubMedCrossRef

DeGramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938–2947CrossRef

Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342PubMedCrossRef

Ezzeldin H, Diasio R (2004) Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 4(3):181–189PubMedCrossRef

Colucci G, Gebbia V, Paoletti G et al (2005) Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’ Italia Meridionale. J Clin Oncol 23(22):4866–4875PubMedCrossRef

Chung KY, Saltz LB (2007) Adjuvant therapy of colon cancer: current status and future directions. Cancer J 13(3):192–197PubMedCrossRef

Board RE, Valle JW (2007) Metastatic colorectal cancer: current systemic treatment options. Drugs 67(13):1851–1867PubMedCrossRef

10.

Sauer R, Liersch T, Merkel S et al (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30(16):1926–1933PubMedCrossRef

11.

Asmis T, Berry S, Cosby R et al (2014) Cancer Care Ontario’s Gastrointestinal Disease Site Group. Strategies of sequential therapies in unresectable metastatic colorectal cancer: a meta-analysis. Curr Oncol 21(6):318–328PubMedPubMedCentralCrossRef

12.

Chua W, Kho PS, Moore MM et al (2011) Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Crit Rev Oncol Hematol 79(3):224–250PubMedCrossRef

13.

Hofheinz RD, Wenz F, Post S at al (2012) Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 13(6):579–588PubMedCrossRef

14.

Li W, Xu J, Shen L, Liu T et al (2014) Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients. BMC Cancer 14:986PubMedPubMedCentralCrossRef

15.

Meta-Analysis Group In Cancer, Lévy E, Piedbois P, Buyse M et al (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16 (11):3537–3541

16.

Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16(4):215–237PubMedCrossRef

17.

Mattison LK, Soong R, Diasio RB (2002) Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 3(4):485–492PubMedCrossRef

18.

Thorn CF, Marsh S, Carrillo MW et al (2011) PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics 21(4):237–242PubMedPubMedCentral

19.

Van Kuilenburg AB, Meinsma R, Zonnenberg BA et al (2003) Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res 9(12):4363–4367PubMed

20.

Van Kuilenburg AB, Maring JG, Schalhorn A et al. (2008) Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14 + 1G > A mutation in the dihydropyrimidine dehydrogenase gene. Nucl Nucl Nucl Acids 27(6):692–698

21.

Amstutz U, Froehlich TK, Largiadèr CR (2011) Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 12(9):1321–1336PubMedCrossRef

22.

Kaldate RR, Haregewoin A, Grier CE et al (2012) Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. Oncologist 17(3):296–302PubMedPubMedCentralCrossRef

23.

Etienne MC, Lagrange JL, Dassonville O et al (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12(11):2248–2253PubMedCrossRef

24.

Cohen V, Panet-Raymond V, Sabbaghian N, Morin I et al (2003) Methylenetetrahydrofolatereductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 9(5):1611–1615PubMed

25.

Sohn KJ, Croxford R, Yates Z et al (2004) Effect of the methylenetetrahydrofolatereductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 96:134–144PubMedCrossRef

26.

Toffoli G, De Mattia E (2008) Pharmacogenetic relevance of MTHFR polymorphisms. Pharmacogenomics 9(9):1195–1206PubMedCrossRef

27.

Kantar M, Kosova B, Cetingul N et al (2009) Methylenetetrahydrofolatereductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 50(6):912–917PubMedCrossRef

28.

World Medical Association Declaration of Helsinki (2008) Ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 59th WMA General Assembly Seoul, South Korea

29.

National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf

30.

Response Evaluation Criteria in Solid Tumors (RECST) https://www.eortc.be/Recist/documents/ RECISTGuidelines.pdf

31.

Islam MS, Ahmed MU, Sayeed MS et al (2013) Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population. Clin Chim Acta 416:11–19PubMedCrossRef

32.

Ma Q, Lu AY (2011) Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 63(2):437–459PubMedCrossRef

33.

Stewart CF, Schuetz EG (2000) Need and potential for predictive tests of hepatic metabolism of anticancer drugs. Clin Cancer Res 6(9):3391–3392PubMed

34.

Chua W, Goldstein D, Lee CK et al (2009) Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer 101(6):998–1004PubMedPubMedCentralCrossRef

35.

Huang RS, Ratain MJ (2009) Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 59(1):42–55PubMedPubMedCentralCrossRef

36.

Van Kuilenburg AB, Vreken P, Beex LV et al (1997) Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Eur J Cancer 33(13):2258–2264PubMedCrossRef

37.

Vreken P, Vankuilenburg ABP, Meinsma R et al (1996) A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J Inherit Metab Dis 19(5):645–654PubMedCrossRef

38.

Wei X, McLeod HL, McMurrough J et al (1996) Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 98:610–615PubMedPubMedCentralCrossRef

39.

Ciccolini J, Mercier C, Evrard A et al (2006) A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit 8(5):678–685CrossRef

40.

Van Kuilenburg AB, Haasjes J, Meinsma R et al (2000) Dihydropyrimidine dehydrogenase (DPD) deficiency: novel mutations in the DPD gene. Adv Exp Med Biol 486:247–250PubMedCrossRef

41.

Boisdron-Celle M, Remaud G, Traore S et al (2007) 5-fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 249(2):271–282PubMedCrossRef

42.

Terrazzino S, Cargnin S, Del Re M et al (2013) DPYD IVS14 + 1G > A and 2846A > T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics 14(11):1255–1272PubMedCrossRef

43.

Van Kuilenburg AB, Haasjes J, Van Lenthe H et al (2000) Dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil associated toxicity. Adv Exp Med Biol 486:251–255PubMedCrossRef

44.

Van Kuilenburg AB, Dobritzsch D, Meinsma R et al (2002) Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three dimensional protein structures. Biochem J 364(Pt 1):157–163PubMedPubMedCentralCrossRef

45.

Schwab M, Zanger UM, Marx C et al (2008) Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 26(13):2131–2138PubMedCrossRef

46.

Gross E, Busse B, Riemenschneider M et al. (2008) Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS One 3 (12), e4003

47.

Cho H, Park Y, Kang W, Kim J, Lee S (2007) Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity. Ther Drug Monit 29(2):190–196PubMedCrossRef

48.

Maekawa K, Saeki M, Saito Y et al (2007) Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences. J Hum Genet 52(10):804–819PubMedCrossRef

49.

Morel A, Boisdron-Celle M, Fey L et al (2006) Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 5(11):2895–2904PubMedCrossRef

50.

Frosst P, Blom HJ, Milos R et al (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolatereductase. Nat Genet 10:111–113PubMedCrossRef

51.

Yeh CC, Lai CY, Chang SN et al (2017) Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy. Int J Clin Oncol 2:1–10

52.

Etienne MC, Formento JL, Chazal M et al (2004) Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenet Genom 14(12):785–792CrossRef

53.

Etienne MC, Ilc K, Formento JL et al (2004) Thymidylate synthase and methylenetetrahydrofolatereductase gene polymorphisms: relationships with 5-fluorouracil sensitivity. Br J Cancer 90:526–534PubMedPubMedCentralCrossRef

54.

Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J (2005) Thymidylate synthase and methylenetetrahydrofolatereductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 23:1365–1369PubMedCrossRef

55.

Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F et al (2010) Methylenetetrahydrofolatereductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol 69(1):58–66PubMedPubMedCentralCrossRef

56.

Marcuello E, Altés A, Menoyo A et al (2006) Methylenetetrahydrofolatereductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol 57:835–840PubMedCrossRef

57.

Sharma R, Hoskins JM, Rivory LP et al (2008) Thymidylate synthase and methylenetetrahydrofolatereductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res 14:817–825PubMedCrossRef

Titel: DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer
verfasst von: Noor Ahmed Nahid
Mohd Nazmul Hasan Apu
Md. Reazul Islam
Samia Shabnaz
Surid Mohammad Chowdhury
Maizbha Uddin Ahmed
Zabun Nahar
Md. Siddiqul Islam
Mohammad Safiqul Islam
Abul Hasnat
Publikationsdatum: 13.11.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 1/2018
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-017-3478-3

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Therapeutic potential of the metabolic modulator Metformin on osteosarcoma cancer stem-like cells

The earlier, the better: the effects of different administration timepoints of sorafenib in suppressing the carcinogenesis of VEGF in rats

Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia

Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects

Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie